Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus amyloliquefaciens
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical, Soil Application
01
Overview
*Bacillus amyloliquefaciens* is a Gram-positive, aerobic, spore-forming bacterium widely utilized as a biocontrol agent in agriculture and a probiotic in animal nutrition and human health. It belongs to the *Bacillus subtilis* species complex and is characterized by its robust ability to colonize the rhizosphere and gastrointestinal tract. Its primary mechanism of action involves the synthesis of a diverse array of secondary metabolites, including cyclic lipopeptides (surfactin, iturin, and fengycin) and polyketides (difficidin, macrolactin), which exhibit potent antifungal and antibacterial activities. In plants, it triggers induced systemic resistance (ISR) by activating jasmonic acid and ethylene signaling pathways. In animals, specific strains enhance intestinal barrier function, modulate immune responses, and alleviate oxidative stress. Additionally, it is a significant industrial source of enzymes such as alpha-amylase and proteases, and is employed in the biodegradation of mycotoxins like aflatoxin B1 and zearalenone.
- Brand names
- SerenadeDouble Nickel 55TaegroEcobiolDisease Pro Ba
- Other names
- B. amyloliquefaciensBacillus amyloliquefaciens plantarum
02
Targets
PGN (Peptidoglycan)
Beyond the preview
Go deeper on bacillus amyloliquefaciens.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus amyloliquefaciens.